Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
Perimenis
Petros
P
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002243:Carbolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011687:Purines; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068581:Tadalafil; D014227:Triazines / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
D002243:Carbolines; D007093:Imidazoles; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human